Literature DB >> 8036680

High dose of primaquine in primaquine resistant vivax malaria.

D Bunnag1, J Karbwang, A Thanavibul, S Chittamas, Y Ratanapongse, K Chalermrut, K N Bangchang, T Harinasuta.   

Abstract

The efficacy of low dose chloroquine, characteristic pattern of relapse and the relapse rate in vivax malaria after high dose primaquine were investigated in 167 Thai patients. 87 patients were allocated at random to receive 300 mg, and 80 received 450 mg of chloroquine on the first day of admission. All patients in both groups showed a rapid response with comparable fever clearance times (27.3 vs. 26.1 h) and parasite clearance times (67.1 vs. 58.1 h). After recovery and clearance of parasitaemia, the patients were allocated at random (double blind) to receive 2 dosage regimens of primaquine, a daily dose of 15 mg or 22.5 mg for 14 d. Relapses in both groups occurred within 6 months; no patient relapsed beyond that period. The relapse rate in the primaquine 15 mg group was significantly higher than that in the 22.5 mg group (17.5% vs. 2.4%).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8036680     DOI: 10.1016/0035-9203(94)90305-0

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  22 in total

Review 1.  A pre-emptive strike against malaria's stealthy hepatic forms.

Authors:  Dominique Mazier; Laurent Rénia; Georges Snounou
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

Review 2.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

3.  A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand.

Authors:  Sasithon Pukrittayakamee; Mallika Imwong; Kesinee Chotivanich; Pratap Singhasivanon; Nicholas P J Day; Nicholas J White
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

4.  Naphthylisoquinoline alkaloids against malaria: evaluation of the curative potentials of dioncophylline C and dioncopeltine A against Plasmodium berghei in vivo.

Authors:  G François; G Timperman; W Eling; L A Assi; J Holenz; G Bringmann
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand.

Authors:  Srivicha Krudsood; Polrat Wilairatana; Noppadon Tangpukdee; Kobsiri Chalermrut; Siripun Srivilairit; Vipa Thanachartwet; Sant Muangnoicharoen; Natthanej Luplertlop; Gary M Brittenham; Sornchai Looareesuwan
Journal:  Korean J Parasitol       Date:  2006-09       Impact factor: 1.341

6.  High-dose primaquine regimens against relapse of Plasmodium vivax malaria.

Authors:  Srivicha Krudsood; Noppadon Tangpukdee; Polrat Wilairatana; Nantaporn Phophak; J Kevin Baird; Gary M Brittenham; Sornchai Looareesuwan
Journal:  Am J Trop Med Hyg       Date:  2008-05       Impact factor: 2.345

Review 7.  Vivax malaria: neglected and not benign.

Authors:  Ric N Price; Emiliana Tjitra; Carlos A Guerra; Shunmay Yeung; Nicholas J White; Nicholas M Anstey
Journal:  Am J Trop Med Hyg       Date:  2007-12       Impact factor: 2.345

Review 8.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Is the malaria diagnosis expensive?

Authors:  P Penin; E Vázquez; R Martínez; J A de Diego
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

10.  Molecular and epidemiological characterization of Plasmodium vivax recurrent infections in southern Mexico.

Authors:  Lilia Gonzalez-Ceron; Jianbing Mu; Frida Santillán; Deirdre Joy; Marco A Sandoval; Gerardo Camas; Xinzhuan Su; Elena V Choy; Rene Torreblanca
Journal:  Parasit Vectors       Date:  2013-04-18       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.